Background: Patients with chronic heart failure (CHF) benefit from treatment for iron deficiency by having better
cardiac and renal function.
Objective: To evaluate the relationship of serum biomarkers of iron stores with CHF in nondialysis chronic kidney
disease (CKD) patients, with or without anemia and to evaluate the therapeutic effect of iron sucrose administration for
HF patients with iron deficiency.
Patients and Methods: This prospective study was conducted on 143 patients with CHF with eGFR < 60 ml/min/1.73
m2
for evaluation the association of TSAT and serum ferretin level categories with all clinical, biochemical
characteristics, NYHA functional class and echocardiographic findings. Only 100 patients were selected and
randomized into two groups (control group and iron sucrose group) and followed up by echocardiography for 3 months.
Results: There were statistically significant differences in clinical, biochemical and echocardiographic parameters
between iron stores level categories with better outcomes in higher TSAT and s. ferretin level categories. Intravenous
iron was associated with improved renal function (both p |
